A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer

NCT00077857 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

470

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: capecitabine (Xeloda®)
DRUG: docetaxel (Taxotere®)

Sponsor

Hoffmann-La Roche